Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Prelude Therapeutics Inc

Healthcare US PRLD

4.49USD
0.38(9.25%)

Last update at 2026-06-12T20:00:00Z

Day Range

4.004.52
LowHigh

52 Week Range

1.666.03
LowHigh

Fundamentals

  • Previous Close 4.11
  • Market Cap203.79M
  • Volume314179
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-136.18800M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-1.69

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -115.43800M -111.69400M -56.92900M -27.57000M -14.68000M
Minority interest - - - - -
Net income -107.33600M -110.77900M -56.92900M -27.57000M -14.68000M
Selling general administrative 30.65M 26.96M 10.59M 3.83M 2.35M
Selling and marketing expenses - - - - -
Gross profit - - - - -
Reconciled depreciation 1.32M 0.92M 0.54M 0.38M 0.15M
Ebit -124.86400M -114.65000M -58.76300M -28.10900M -14.97500M
Ebitda -123.54000M -113.73500M -58.22100M -27.72700M -14.82600M
Depreciation and amortization 1.32M 0.92M 0.54M 0.38M 0.15M
Non operating income net other - - - - -
Operating income -123.54000M -113.73500M -58.76300M -28.10900M -14.97500M
Other operating expenses 123.54M 113.73M 58.76M 28.11M 14.97M
Interest expense 1.32M 2.04M 0.00000M 0.00000M 0.00000M
Tax provision - - - - -
Interest income - - - - -
Net interest income - - - - -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -8.10200M -0.91500M -1.83400M -0.53900M 0.29M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 123.54M 113.73M 58.76M 28.11M 14.97M
Cost of revenue - - - - -
Total other income expense net 8.10M 2.04M 1.83M 0.54M 0.29M
Discontinued operations - - - - -
Net income from continuing ops -115.43800M -111.69400M -56.92900M -27.57000M -14.68000M
Net income applicable to common shares -115.43800M -111.69400M -56.92900M -27.57000M -14.68000M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 277.67M 220.50M 305.10M 223.59M 21.87M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 2.65M 2.65M 3.88M 2.50M 1.34M
Total liab 40.58M 25.06M 19.20M 11.41M 71.28M
Total stockholder equity 237.09M 195.44M 285.90M 212.18M -49.41200M
Deferred long term liab - - - 0.30M -
Other current liab 0.94M 13.09M 9.62M 7.46M 2.60M
Common stock 0.00500M 0.00500M 0.00500M 0.00400M -
Capital stock 0.00500M 0.00500M 0.00500M 0.00400M 0.00000M
Retained earnings -456.39000M -334.55800M -219.12000M -107.42600M -50.49700M
Other liab - 3.36M - 0.03M 0.00500M
Good will - - - - -
Other assets - 9.42M 4.35M 0.30M -
Cash 25.29M 30.61M 31.83M 218.31M 18.88M
Cash and equivalents - - - - -
Total current liabilities 21.83M 21.70M 19.20M 11.38M 4.83M
Current deferred revenue 14.82M - - - -
Net debt -8.40300M -28.77300M -30.08800M -218.30900M -18.62100M
Short term debt 1.48M 1.83M 1.74M - 0.26M
Short long term debt - - - - -
Short long term debt total 16.89M 1.83M 1.74M - 0.26M
Other stockholder equity 693.25M 531.68M 505.72M 319.61M 1.08M
Property plant equipment - 6.70M 5.64M 2.48M 1.65M
Total current assets 235.59M 204.38M 295.12M 220.81M 20.22M
Long term investments - - - - -
Net tangible assets - 195.44M 285.90M 212.18M -49.41200M
Short term investments 207.64M 171.12M 259.40M - -
Net receivables - - - - -
Long term debt - - - - -
Inventory - - - - -
Accounts payable 4.58M 6.78M 7.84M 3.92M 1.97M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.22M -1.69200M -0.71100M -223.59000M -0.55600M
Additional paid in capital - - - - -
Common stock total equity - - - 0.00400M -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.30M 9.42M 4.35M 0.30M -
Deferred long term asset charges - - - - -
Non current assets total 42.08M 16.12M 9.98M 2.78M 1.65M
Capital lease obligations 16.89M 1.83M 1.74M 0.00000M 0.26M
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 81.69M -263.80300M -0.62100M -0.78000M -0.52900M
Change to liabilities -0.34700M 3.90M 1.16M 0.55M 0.72M
Total cashflows from investing activities 81.69M -263.80300M -0.62100M -0.78000M -0.52900M
Net borrowings - - -0.25800M -0.12400M -0.12400M
Total cash from financing activities 0.81M 164.90M 246.23M 29.73M 17.94M
Change to operating activities 1.28M -0.27800M 3.46M 0.12M 0.66M
Net income -115.43800M -111.69400M -56.92900M -27.57000M -14.68000M
Change in cash -1.22300M -182.43700M 199.43M 3.28M 4.45M
Begin period cash flow 35.87M 218.31M 18.88M 15.60M 11.14M
End period cash flow 34.65M 35.87M 218.31M 18.88M 15.60M
Total cash from operating activities -83.72900M -83.53100M -46.17700M -25.66500M -12.95400M
Issuance of capital stock 0.00000M 161.42M 246.40M 29.85M 17.94M
Depreciation 1.32M 0.92M 0.54M 0.38M 0.15M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock - - - - -
Other cashflows from financing activities 0.43M 3.47M 79.86M 29.85M 17.94M
Change to netincome 29.45M 23.62M 5.59M 0.86M 0.20M
Capital expenditures 3.02M 2.32M 0.62M 0.78M 0.53M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 0.93M 3.62M 4.62M 0.67M 1.38M
Stock based compensation 25.14M 20.93M 5.58M 0.85M 0.18M
Other non cash items 4.31M 1.33M 0.01M 0.01000M 0.01M
Free cash flow -86.74800M -85.85400M -46.79800M -26.44500M -13.48300M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
PRLD
Prelude Therapeutics Inc		 0.38 9.25% 4.49 - - - 1.32 -0.7315
NVO
Novo Nordisk A/S		 -0.08 0.18% 43.88 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.99 4.74% 44.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -0.115 0.03% 444.93 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 0.66 0.11% 612.14 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.

Prelude Therapeutics Inc

175 Innovation Boulevard, Wilmington, DE, United States, 19805

Key Executives

Name Title Year Born
Dr. Krishna Vaddi D.V.M., Ph.D. Founder, CEO & Director 1966
Dr. Peggy A. Scherle Ph.D. Chief Scientific Officer 1961
Dr. Andrew P. Combs Ph.D. Exec. VP & Head of Chemistry 1966
Dr. Edna Huang M.D. Pres & Chief Medical Officer 1973
Mr. Laurent Chardonnet Chief Financial Officer 1965
Ms. Aimee Crombie Ph.D. Sr. VP and Head of Strategic Planning & Operations NA
Dr. Madhu Pudipeddi Ph.D. Sr. VP of Technical Operations NA
Ms. Michele Porreca M.B.A. Chief People Officer NA
Mr. Naveen Babbar Ph.D. Sr. VP of Translation Medicine NA
Dr. Neelesh Sharma M.D., Ph.D. Sr. VP of Clinical Devel. NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions